Fierce Pharma

MARCH 11, 2024

The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended, as the FDA has approved the first drug for the fatty liver disease. | The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended. The FDA has approved Madrigal's resmetirom under the brand name Rezdiffra as the first drug for the fatty liver disease.

FDA 350

FDA Biopharma 350

Pharmaceutical Technology

MARCH 11, 2024

Upcoming regulatory events for pipeline AAV gene therapies, with a focus on neuromuscular and blood disorders, are setting high expectations for the space in 2024.

119

119

Fierce Pharma

MARCH 11, 2024

Bluebird Bio has secured its first Medicaid outcomes-based agreement for its sickle cell disease gene therapy Lyfgenia, signing on with Michigan.

321

321

pharmaphorum

MARCH 11, 2024

Shares in Amylyx have cratered after the company reported a confirmatory trial of its amyotrophic lateral sclerosis (ALS) therapy Relyvrio missed all its objectives, putting its accelerated approval in jeopardy.

116

116

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

MARCH 11, 2024

After a pair of approvals in recent years and as its sales continue to climb, Incyte's topical JAK inhibitor Opzelura is adding to its clinical case with trial results that demonstrate its benefits | The company presented positive data from a phase 2 study in mild-to-moderate hidradenitis suppurativa at the American Academy of Dermatology's annual meeting on Sunday.

Sales 294

Sales 294

pharmaphorum

MARCH 11, 2024

J&J says oral IL-23 inhibitor JNJ-2113 shows a durable effect in psoriasis, making it a potential companion to its injectable Tremfya.

114

114

pharmaphorum

MARCH 11, 2024

Novo Nordisk’s Wegovy has been given a first-in-class approval by the FDA to reduce the risk of serious cardiovascular conditions in people who are overweight or obese

FDA 111

FDA 111

Fierce Pharma

MARCH 11, 2024

Ever since its first FDA rejection five years ago, Lexicon Pharmaceuticals hasn’t given up hope on its Type 1 diabetes prospect sotagliflozin. | The company hopes its long and bumpy five-year journey will soon see an end with an FDA approval. Lexicon looks to resubmit the drug by the middle of the year.

FDA 262

FDA Prospecting Pharmaceutical 262

pharmaphorum

MARCH 11, 2024

Boehringer Ingelheim has taken an option on a family of GPR52 agonist compounds with potential in schizophrenia from Sosei Heptares, in a €755m deal

105

105

Fierce Pharma

MARCH 11, 2024

Ahead of a high-stakes FDA meeting to review CAR-T data in multiple myeloma, Legend Biotech CEO Ying Huang, Ph.D., laid out some of his expectations about the event. | J&J and Legend have submitted two more overall survival updates for Caryvkti since the original data release last year, Legend's CEO said on an analyst call. The FDA is expected to release more data on the CAR-T therapy later this week, ahead of an advisory committee meeting set for Friday.

FDA 182

FDA 182

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

MedCity News

MARCH 11, 2024

On Monday at HIMSS24, Innovaccer unveiled a preview of its new AI copilot for providers, which is slated to go on the market by the end of 2024. The solution is a portable tablet device designed to provide clinicians with point-of-care support — it flags care and coding gaps, assists with clinical documentation and advises clinicians on possible diagnosis pathways.

Marketing 104

Marketing Healthcare Healthcare 104

Pharmaceutical Commerce

MARCH 11, 2024

A USC study discovers that an increasing share of both generic and brand-name meds are being excluded from approval.

104

104

MedCity News

MARCH 11, 2024

We can no longer simply worry about the enrollment form as the only hurdle in therapy initiation. We must view the entire patient journey as an interconnected set of challenges that need solving. And I believe achieving that goal is within reach.

Medical 101

Medical Patients Biopharma 101

PharmaTimes

MARCH 11, 2024

The neurodevelopmental condition affects up to four in 100 children

101

101

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

European Pharmaceutical Review

MARCH 11, 2024

Since the HIV epidemic began in the early 1980s, more than 85 million people have been diagnosed worldwide and about 40 million have died as a result of complications from the virus. 1 Now, four decades later, 39 million people around the world are living with HIV, primarily due to advances in treatment. 1 With continued innovation on the horizon in terms of prevention and treatment methods, what was once a wishful hope of ending the epidemic has become a conceivable goal.

Medicine 98

Medicine Pharmacology Healthcare Healthcare 98

Pharmaceutical Technology

MARCH 11, 2024

Boehringer Ingelheim has entered a deal with Sosei Heptares for the development of treatments for all schizophrenia symptoms.

98

98

European Pharmaceutical Review

MARCH 11, 2024

In a review on fungal-contaminated compounded pharmaceuticals and medical devices, researchers have described how the contamination of these products can be due to breaches in sterile compounding procedures. The authors explained: “inadequate sterile compounding techniques or storage conditions, or exceeding the limit of a fungal count, can result in fungal contamination.

Pharmaceutical 98

Pharmaceutical Food and Drug Administration Manufacturing Pharmaceutical products 98

MedCity News

MARCH 11, 2024

Episode 2 of the Debunked (audio) show focuses on how hospitals are inflating prices for outpatient procedures and how California is looking at healthcare M&A and trying to address price increases and anti-competitive behavior.

Competition 97

Competition Healthcare Healthcare 97

Advertisement

European Pharmaceutical Review

MARCH 11, 2024

The manufacturer Olympus Corporation has announced the rescission of an earlier acquisition deal due to reported data integrity issues of medical device products from Taewoong Medical Co., Ltd. Olympus originally announced the closing of its agreed share acquisition of Taewoong Medical in January 2024. Data integrity issues The concerns around these products were found after the closing of the deal, Olympus noted.

Manufacturing 98

Manufacturing Medical Pharmaceutical 98

PharmaTimes

MARCH 11, 2024

The HYPIEND project consists of 14 partners from eight European countries

81

81

Pharmaceutical Technology

MARCH 11, 2024

Sun Pharma has announced a recall of 55,000 bottles of Febuxostat, a medication used to treat gout, from the US market

Pharma 80

Pharma Medical Marketing 80

MedCity News

MARCH 11, 2024

Sosei Heptares’ schizophrenia drug candidate addresses a novel, difficult-to-drug target for neurological disorders. Boehringer Ingelheim can exercise its option on the small molecule following a Phase 1 test expected to yield data in 2025.

Biopharma 75

Biopharma Pharma 75

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

Pharmaceutical Technology

MARCH 11, 2024

Discover how 4D Molecular Therapeutics Inc. is revolutionizing gene therapy with a patent for delivering nucleic acids to treat disorders like Fabry disease.

74

74

MedCity News

MARCH 11, 2024

By eliminating the term “obesity” in favor of person-centric language, we pave the way for a more equitable healthcare system that prioritizes the well-being of all individuals, regardless of their size or shape.

Healthcare 64

Healthcare Healthcare Management 64

PharmaVoice

MARCH 11, 2024

One rare disease survivor’s diagnosis experience highlights the need for pharma companies to better understand the patient journey.

Pharma 64

Pharma Patients 64

Pharmacy Times

MARCH 11, 2024

Contract pharmacies should work to stay in a perpetual state of audit readiness

Management 59

Management 59

Advertisement

Distribution

Pharmaceutical Technology

MARCH 11, 2024

The race for the first FDA-approved cell therapy for patients with heart failure heats up.

FDA 59

FDA Patients 59

Pharmacy Times

MARCH 11, 2024

The IVIG therapies were previously approved for 4-week room temperature storage conditions of 25º Celsius during the first 24 months of shelf life.

FDA 59

FDA 59

Pharmaceutical Technology

MARCH 11, 2024

Celltrion has filed a BLA with the US FDA for a biosimilar candidate to XOLAIR (omalizumab), CT-P39, for chronic spontaneous urticaria (CSU).

FDA 59

FDA 59

Pharmacy Times

MARCH 11, 2024

If clinical trials continue to show that psychedelics offer safe and long-lasting results, then psychedelic-assisted therapy could flourish as a treatment in the mental health space.

52

52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales